Tango Therapeutics (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$21.00
▼(-21.17% Downside)
Action:Reiterated
Date:06/05/26
The score is primarily held back by persistent losses and significant cash burn despite strong gross margins, with only partial offset from a relatively strong, low-leverage balance sheet. Technicals are neutral-to-soft (negative MACD; near-term averages overhead), and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Balance sheet strength / low leverage
Very low leverage and a strong equity base provide durable financial flexibility for a development-stage biotech. This reduces immediate refinancing pressure, supports sustained R&D funding through clinical inflection points, and allows management to pursue costly pivotal trials without urgent deleveraging.
Negative Factors
Sizable ongoing cash burn
Persistent large negative operating and free cash flow is a structural risk for a pre-revenue biotech: it necessitates periodic capital raises or partner milestones to fund operations. Continued high burn can force dilution, limit program breadth, and compress runway if milestone payments or financing become delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength / low leverage
Very low leverage and a strong equity base provide durable financial flexibility for a development-stage biotech. This reduces immediate refinancing pressure, supports sustained R&D funding through clinical inflection points, and allows management to pursue costly pivotal trials without urgent deleveraging.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.20B
Dividend YieldN/A
Average Volume (3M)3.04M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth39.04%
EPS Growth32.40%
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding144,647,980
10 Day Avg. Volume3,795,201
30 Day Avg. Volume3,037,748
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue42.61
Enterprise Value/Gross Profit43.81
Enterprise Value/Ebitda-21.44
Forecast
1Y Price Target
$32.44Price Target Upside21.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$6.06M
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as...
How the Company Makes Money
As a clinical-stage biotechnology company, Tango Therapeutics primarily generates revenue from collaboration and licensing arrangements rather than from product sales, because it does not have broadly available commercial drugs on the market. Its ...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.99M | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 55.42M | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -113.26M | -109.01M | -143.10M | -111.76M | -109.46M | -57.29M |
| Net Income | -107.23M | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | ||||||
| Total Assets | 435.79M | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 379.84M | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 32.79M | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 44.29M | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 391.51M | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | ||||||
| Free Cash Flow | -142.54M | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -141.55M | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -61.83M | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 302.34M | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Negative
26.64
Price Trends
22.47
Negative
18.20
Positive
13.26
Positive
Market Momentum
-0.37
Positive
43.85
Neutral
45.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Negative. The current price of 26.64 is above the 20-day moving average (MA) of 21.75, above the 50-day MA of 22.47, and above the 200-day MA of 13.26, indicating a neutral trend. The MACD of -0.37 indicates Positive momentum. The RSI at 43.85 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.76B | -28.54 | -25.99% | ― | ― | 54.61% | |
48 Neutral | $404.34M | -2.44 | -43.82% | ― | ― | ― | |
47 Neutral | $3.20B | -27.07 | -41.54% | ― | 39.04% | 32.40% | |
47 Neutral | $900.68M | -4.29 | -153.61% | ― | 1.92% | -1130.30% | |
44 Neutral | $1.37B | -5.33 | -45.47% | ― | -72.09% | -754.83% | |
42 Neutral | $626.74M | -2.73 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
TNGX
Tango Therapeutics
20.22
15.96
374.65%
ORKA
Oruka Therapeutics
60.14
47.56
378.06%
IMTX
Immatics
9.79
3.82
63.99%
SPRY
ARS Pharmaceuticals
8.56
-5.93
-40.92%
PRME
Prime Medicine, Inc.
3.06
1.37
81.07%
UPB
Upstream Bio, Inc.
7.05
-4.22
-37.44%
Tango Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Tango Therapeutics Holds 2026 Virtual Annual Stockholder Meeting
Positive
Jun 4, 2026
Tango Therapeutics held its 2026 annual meeting of stockholders in a virtual-only format on June 4, 2026, with 131,198,081 shares represented, or 90.96% of the 144,242,271 outstanding common shares entitled to vote as of the April 7, 2026 record d...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Tango Therapeutics Reshapes Board Amid Late-Stage Progress
Positive
May 13, 2026
On May 12, 2026, Tango Therapeutics announced that directors Alexis Borisy and Kanishka Pothula resigned from the board, effective May 13, 2026, with no disagreements cited over company practices. Sung Lee was appointed Lead Independent Director, ...
Executive/Board Changes
Tango Therapeutics Finalizes Separation Agreement with Former CFO
Neutral
May 8, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer and principal financial officer Daniella Beckman would leave her roles, effective April 15, 2026, with her last day of employment recorded as May 1, 2026. On M...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push
Positive
Apr 15, 2026
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer Daniella Beckman would depart her roles effective April 15, 2026, and appointed veteran biotech finance executive Matthew Gall as CFO and principal financial o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.